UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension Saqib Islam, SpringWorks Therapeutics CEO Saqib Islam, SpringWorks Therapeutics CEO SpringWorks Therapeutics, Inc SpringWorks Therapeutics, Inc. GOMEKLI™ (mirdametinib) logo GOMEKLI™ (mirdametinib) logo – GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data from Phase 2b ReNeu trial, which sho ...